What is the significance of the CE Mark submission for the Hugo™ system?

The CE Mark submission is a critical milestone for Medtronic, as obtaining it will allow the Hugo™ soft-tissue robotic system to be marketed and sold within the European Economic Area (EEA). This is a major step towards commercialization in a significant global market.

What does filing for an IDE with the U.S. FDA mean for Medtronic?

Filing for an Investigational Device Exemption (IDE) with the U.S. FDA is the first step in the process to conduct clinical trials in the United States. Approval of the IDE will permit Medtronic to gather the necessary clinical data to support a Premarket Approval (PMA) application, which is required for marketing the Hugo™ system in the U.S.

How will the partnerships with international hospitals benefit Medtronic?

These partnerships are multi-faceted. They allow Medtronic to install and provide training on the Hugo™ system in real-world clinical settings, gather essential data for its global clinical registry, and support regulatory submissions in various international markets. This also helps refine the system and its associated procedures before broader market rollout.

When can investors expect the Hugo™ system to be available in the U.S. market?

This filing is for an IDE, which is the beginning of the U.S. clinical trial process. The time to market for a robotic surgical system after an IDE filing can be lengthy, involving successful completion of clinical trials and subsequent FDA review and approval. Specific timelines were not provided in this release.

MDT 8-K: Regulation FD — Mar 31, 2021

Summary

Medtronic plc (MDT) announced significant progress in the development and regulatory pathway for its Hugo™ soft-tissue robotic system. The company has submitted for Conformité Européenne (CE) Mark approval, a crucial step for market entry in Europe. Concurrently, Medtronic has filed for an investigational device exemption (IDE) with the U.S. Food and Drug Administration (FDA), initiating the process for clinical trials and eventual U.S. market approval. These regulatory submissions, coupled with strategic partnerships with international hospitals and healthcare systems, underscore Medtronic's commitment to advancing its robotic surgery platform. The company's plan to install Hugo™ systems and provide training outside of CE Mark jurisdictions, while also establishing a clinical data registry, demonstrates a proactive approach to gathering data for global regulatory submissions and commercialization efforts. This news is a key indicator of Medtronic's innovation pipeline and its ambition to compete in the growing robotic surgery market.

Key Highlights

1Medtronic has submitted its Hugo™ soft-tissue robotic system for CE Mark approval, indicating progress towards European market entry.
2The company has filed for an Investigational Device Exemption (IDE) with the U.S. FDA, paving the way for clinical trials and U.S. market authorization.
3Medtronic is actively engaging with international hospitals and healthcare systems for the installation and training of Hugo™ systems.
4These partner sites will contribute to Medtronic's global clinical data registry, supporting future regulatory submissions.
5The announcement signals Medtronic's strategic push into the competitive robotic surgery market with a new soft-tissue solution.

Medtronic plc 8-K Report, Regulation FD Disclosure (Mar 31, 2021)

Summary

Key Highlights

Frequently Asked Questions